Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease

Vascular Medicine (United Kingdom)

Volumn 17, Issue 2, 2012, Pages 101-107

  Tabit, Corey E ^a   Holbrook, Monica ^a   Shenouda, Sherene M ^a   Dohadwala, Mustali M ^a   Widlansky, Michael E ^b   Frame, Alissa A ^a   Kim, Brian H ^a   Duess, Mai Ann ^a   Kluge, Matthew A ^a   Levit, Aaron ^a   Keaney, John F ^c   Vita, Joseph A ^a   Hamburg, Naomi M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

coronary artery disease; endothelial function; inflammation; vascular

Indexed keywords

ANTILIPEMIC AGENT; CD69 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PLACEBO; PROTEIN P50; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRACHIAL ARTERY; BRACHIAL ARTERY FLOW MEDIATED DILATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

EID: 84861821346     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X12440117     Document Type: Article

References (37)

1. Gokce N, Keaney JF, Menzoian JO, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation. 2002 ; 105: 1567-1572 (Pubitemid 34297634)
2. Huang AL, Silver AE, Shvenke E, et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2113-2119 (Pubitemid 350287238)
3. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003 ; 42: 1149-1160 (Pubitemid 37188333)
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 ; 105: 1135-1143 (Pubitemid 34212626)
5. Huang AL, Vita JA. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc Med. 2006 ; 16: 15-20 (Pubitemid 43012036)
6. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost. 2009 ; 7: 332-339
7. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002 ; 106: 184-190 (Pubitemid 34761297)
8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 ; 102: 2165-2168
9. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med. 1994 ; 179: 503-512
10. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995 ; 9: 899-909
11. Silver AE, Beske SD, Christou DD, et al. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation. 2007 ; 115: 627-637 (Pubitemid 46226173)
12. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008 ; 28: 1982-1988
13. Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-ΰB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 2009 ; 119: 1284-1292
14. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998 ; 101: 1163-1174 (Pubitemid 28125296)
15. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 ; 353: 259-266 (Pubitemid 29088117)
16. McMackin CJ, Vita JA. Update on nitric oxide-dependent vasodilation in human subjects. Methods Enzymol. 2005 ; 396: 541-553 (Pubitemid 41603575)
17. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008 ; 117: 2467-2474 (Pubitemid 351670453)
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502
19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ; 336: 973-979 (Pubitemid 27152782)
20. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest. 2001 ; 107: 255-264 (Pubitemid 32157955)
21. De Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005 ; 25: 904-914 (Pubitemid 40627833)
22. Brand K, Page S, Rogler G, Bartsch A, Brandl R. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996 ; 97: 1715-1722 (Pubitemid 26105480)
23. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A. 2000 ; 97: 9052-9057 (Pubitemid 30626672)
24. Ritchie ME. Nuclear factor-ΰB is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 1998 ; 98: 1707-1713 (Pubitemid 28492489)
25. Liuzzo G, Santamaria M, Biasucci LM, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 2007 ; 49: 185-194 (Pubitemid 46054391)
26. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004 ; 61: 671-682 (Pubitemid 38249466)
27. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 ; 265: 956-959
28. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998 ; 396: 77-80 (Pubitemid 28520452)
29. Lappas M, Yee K, Permezel M, Rice GE. Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology. 2005 ; 146: 1491-1497 (Pubitemid 40289339)
30. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996 ; 156: 3961-3969 (Pubitemid 26137683)
31. Gupta SK, Johnson RM, Saha C, et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS. 2008 ; 22: 653-655 (Pubitemid 351640600)
32. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?. Lancet. 1997 ; 349: 1391-1392 (Pubitemid 27197552)
33. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002 ; 106: 913-919 (Pubitemid 34925323)
34. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008 ; 201: 318-325
35. Vita JA, Keaney JF, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation. 2004 ; 110: 3604-3609 (Pubitemid 39612578)
36. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000 ; 102: 994-999 (Pubitemid 30657515)
37. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation. 2004 ; 110: 3349-3354 (Pubitemid 39557498)